Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

BACKGROUND: In the evaluation of PD-L1 expression to select patients for anti-PD-1/PD-L1 treatment, uniform guidelines that account for different immunohistochemistry assays, different cell types and different cutoff values across tumor types are lacking. Data on how different scoring methods compar...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Breast Cancer Res
Autores principales: Guo, Hua, Ding, Qingqing, Gong, Yun, Gilcrease, Michael Z., Zhao, Min, Zhao, Jun, Sui, Dawen, Wu, Yun, Chen, Hui, Liu, Hui, Zhang, Jinxia, Resetkova, Erika, Moulder, Stacy L., Wang, Wei-Lien, Huo, Lei
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7310491/
https://ncbi.nlm.nih.gov/pubmed/32576238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01303-9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares